UBS Group’s Guardant Health GH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $130M | Sell |
866,046
-539,791
| -38% | -$58.7M | 0.02% | 945 |
|
|
2026
Q1 | $130M | Sell |
1,405,837
-304,332
| -18% | -$30.6M | 0.02% | 856 |
|
|
2025
Q4 | $175M | Buy |
1,710,169
+253,118
| +17% | +$22.6M | 0.03% | 649 |
|
|
2025
Q3 | $91M | Buy |
1,457,051
+273,232
| +23% | +$14.9M | 0.01% | 1105 |
|
|
2025
Q2 | $61.6M | Sell |
1,183,819
-1,097,242
| -48% | -$49M | 0.01% | 1329 |
|
|
2025
Q1 | $97.2M | Buy |
2,281,061
+525,670
| +30% | +$22.7M | 0.02% | 949 |
|
|
2024
Q4 | $53.6M | Buy |
1,755,391
+1,394,324
| +386% | +$39.2M | 0.01% | 1401 |
|
|
2024
Q3 | $8.28M | Buy |
361,067
+300,623
| +497% | +$8.51M | ﹤0.01% | 2546 |
|
|
2024
Q2 | $1.75M | Sell |
60,444
-69,813
| -54% | -$1.63M | ﹤0.01% | 3901 |
|
|
2024
Q1 | $2.69M | Sell |
130,257
-20,934
| -14% | -$449K | ﹤0.01% | 3640 |
|
|
2023
Q4 | $4.09M | Buy |
151,191
+67,458
| +81% | +$1.77M | ﹤0.01% | 3001 |
|
|
2023
Q3 | $2.48M | Sell |
83,733
-27,695
| -25% | -$974K | ﹤0.01% | 3234 |
|
|
2023
Q2 | $3.99M | Buy |
111,428
+74,953
| +205% | +$2.15M | ﹤0.01% | 2806 |
|
|
2023
Q1 | $855K | Sell |
36,475
-15,066
| -29% | -$430K | ﹤0.01% | 4248 |
|
|
2022
Q4 | $1.4M | Buy |
51,541
+39,556
| +330% | +$1.81M | ﹤0.01% | 3748 |
|
|
2022
Q3 | $645K | Sell |
11,985
-11,800
| -50% | -$606K | ﹤0.01% | 4120 |
|
|
2022
Q2 | $960K | Sell |
23,785
-22,779
| -49% | -$1.13M | ﹤0.01% | 3772 |
|
|
2022
Q1 | $3.08M | Buy |
46,564
+7,233
| +18% | +$495K | ﹤0.01% | 3035 |
|
|
2021
Q4 | $3.93M | Buy |
39,331
+12,756
| +48% | +$1.32M | ﹤0.01% | 3087 |
|
|
2021
Q3 | $3.32M | Buy |
26,575
+243
| +0.9% | +$28.9K | ﹤0.01% | 3117 |
|
|
2021
Q2 | $3.27M | Sell |
26,332
-34,538
| -57% | -$4.65M | ﹤0.01% | 3103 |
|
|
2021
Q1 | $9.29M | Buy |
60,870
+8,831
| +17% | +$1.33M | ﹤0.01% | 2017 |
|
|
2020
Q4 | $6.71M | Buy |
52,039
+16,317
| +46% | +$1.88M | ﹤0.01% | 2175 |
|
|
2020
Q3 | $3.99M | Sell |
35,722
-3,478
| -9% | -$318K | ﹤0.01% | 2404 |
|
|
2020
Q2 | $3.18M | Buy |
39,200
+21,170
| +117% | +$1.71M | ﹤0.01% | 2443 |
|
|
2020
Q1 | $1.25M | Sell |
18,030
-1,900
| -10% | -$146K | ﹤0.01% | 3156 |
|
|
2019
Q4 | $1.56M | Buy |
19,930
+2,589
| +15% | +$187K | ﹤0.01% | 3800 |
|
|
2019
Q3 | $1.11M | Sell |
17,341
-3,622
| -17% | -$319K | ﹤0.01% | 3879 |
|
|
2019
Q2 | $1.81M | Buy |
20,963
+10,390
| +98% | +$794K | ﹤0.01% | 3236 |
|
|
2019
Q1 | $811K | Buy |
10,573
+6,526
| +161% | +$362K | ﹤0.01% | 3734 |
|
|
2018
Q4 | $152K | Buy |
+4,047
| New | +$149K | ﹤0.01% | 5172 |
|
Other funds holding GH
DTC
UBS Group's GH Position: Q2 2026 in Review
UBS Group reduced its Guardant Health (GH) stake by 38% in Q2 2026, selling an estimated $58.7M and leaving 866,046 shares worth $130M. The position accounts for 0.02% of the portfolio, ranked #945.
UBS Group first reported a position in GH in Q4 2018 and has held it in 31 quarters since. The position peaked at $175M in Q4 2025. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.
- UBS Group held 866,046 shares of Guardant Health worth $130M as of Q2 2026.
- UBS Group sold 539,791 Guardant Health shares in Q2 2026, an estimated $58.7M.
- Guardant Health made up 0.02% of UBS Group's portfolio in Q2 2026, its #945 holding.
- UBS Group first reported a position in Guardant Health in Q4 2018 and has held it in 31 quarters since.
- UBS Group's Guardant Health position peaked at $175M in Q4 2025.
- 597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.